ArticleFrontiers in public health2026
Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in Thailand.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HBV/HCV coinfection and anti-tuberculosis drug-induced liver injury: from risk assessment and exploration of mechanisms to preventive considerations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- A pharmacist-led framework for antibiotic-associated liver injury: from pharmacovigilance signals to bedside surveillance with the updated RUCAM and susceptibility markers.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Isoniazid is metabolized by the N-acetyltransferase 2 (NAT2) enzyme. Individuals classified as slow acetylators are increased risk of developing hepatotoxicity. This study aims to evaluate the clinical and economic impact of incorporating NAT2 genotype-guided dosing of isoniazid to prevent anti-tuberculosis drug-induced hepatitis in the Thai healthcare system. Methods: A decision tree and Markov model were developed to assess the costs, clinical outcomes, and quality-adjusted life years (QALYs) of NAT2 genotype-guided isoniazid dosing compared to the standard regimen in newly diagnosed pulmonary tuberculosis patients in Thailand. The primary outcomes were costs, QALYs, and incremental cost-effectiveness ratios (ICERs). Results: The analysis revealed that the discounted costs for the NAT2 genotype-stratified isoniazid dosing group were 28,538 THB (USD 870), compared to 18,727 THB (USD 570) for the standard regimen. The corresponding discounted QALYs were 9.92 years and 7.66 years, respectively. The ICER was 4,333 THB (USD 132) per QALY gained. One-way sensitivity analysis showed that the intervention was cost-effective across all input parameters. Probabilistic sensitivity analysis indicated that 99.98% of simulations were below the threshold for cost-effectiveness. Conclusion: Stratified isoniazid dosing by NAT2 genotype would be cost-effective in treatment of pulmonary tuberculosis in Thailand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.